Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

JO 1784

Known as: JO-1784 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Previous studies from our laboratory have demonstrated that low doses of selective sigma (σ) ligands potentiate the neuronal… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Highly Cited
2001
Highly Cited
2001
Sigma receptors were first described in 1976 as opiate receptors but were later determined to be a distinct class of receptors… Expand
Highly Cited
1999
Highly Cited
1999
Extracellular single-unit recordings and iontophoresis were used to examine the effects of different selective sigma receptor… Expand
Highly Cited
1996
Highly Cited
1996
We have previously shown in vivo that low doses of selective sigma (sigma) receptor ligands potentiate selectively and dose… Expand
1996
1996
Middle cerebral artery occlusion (MCAO) is a widely used surgical procedure for inducing focal cortical ischaemia in mice. In the… Expand
1995
1995
To assess the effects of the novel sigma receptor ligand JO 1784 ((+)-N-cyclopropyl-methyl-N-methyl-1,4-diphenyl-1-yl-but-3-en-1… Expand
Highly Cited
1994
Highly Cited
1994
1 The in vivo effects of the high affinity sigma ligands 1,3‐di(2‐tolyl)guanidine (DTG), (+)‐N‐cyclopropylmethyl‐N‐methyl‐1,4… Expand
Highly Cited
1992
Highly Cited
1992
We have reported previously that the high affinity sigma ligand DTG potentiates N-methyl-D-aspartate (NMDA)-induced excitation of… Expand
1992
1992
The effects of neuropeptide Y (NPY), sigma ligand (JO 1784) and sulfated cholecystokinin octapeptide (CCK8s) on emotional stress… Expand
Highly Cited
1991
Highly Cited
1991
JO 1784 ((+)-N-Cyclopropyl-methyl-N-methyl-1,4-diphenyl-1-yl-but-3-en-1-ylami ne, hydrochloride), has been recently described as… Expand